In contrast, in an aggressive CLL mouse model, FOXO1 was shown to be a driver of disease through induction of IGF1R in PI3K-inhibitor-resistant SLO tumours: this was attenuated by pharmacological FOXO1 inhibition (AS1842856) (107). This evidence concerns the gene FOXO1 and neoplasm.